Frost & Sullivan releases the 'Blue Book on the Current Industry Development and Future Trends of Medical Beauty Injection Products for 2025'

Medical beauty injection products mainly include hyaluronic acid, collagen, regenerative preparations represented by polylactic acid, botulinum toxin, etc. Among them, hyaluronic acid, collagen, and regenerative materials all belong to the category of injectable materials for plastic surgery and cosmetic use in the medical device field. Although botulinum toxin is also widely used in the medical beauty injection field, it falls under the category of toxic drugs for medical use. In addition, in recent years, new materials such as hydroxyapatite, agarose, and elastin have also continuously emerged, presenting a more diversified development trend for medical beauty injection products.

Source: Analysis by Frost & Sullivan

In the field of medical aesthetics injection products, its complete industrial chain is tightly linked by three core links: upstream raw material/device manufacturers, midstream product manufacturers, and downstream service providers and end consumers.

According to data analysis by Frost & Sullivan, the market scale of the injectable cosmetic retail segment in China has soared from 257 billion yuan in 2018 to 670 billion yuan in 2023, with a compound annual growth rate of up to 21.1%.

After 2023, the retail market for medical aesthetics injections in China will continue to maintain high-speed growth. It is estimated that by 2027, the retail market for medical aesthetics injections in China will reach 147 billion RMB, with a compound annual growth rate of 21.7%.

The overall Chinese medical beauty market is undergoing a phase of adjustment after an early period of rapid expansion. According to the analysis by the Artery Network database, the number of financing events in the Chinese medical beauty sector peaked at 71 in 2021; the financing amount reached a high in 2019 (US$1.023 billion) and 2020 (US$1.015 billion). It can be seen that investment and financing in the Chinese medical beauty industry are shifting from 'scale expansion' to 'in-depth technology development'. Capital is focusing on biopolymer innovation and equipment localization. At the same time, policy compliance and consumption upgrading are jointly shaping a new industry pattern, which is expected to form a hierarchical competitive structure of 'technology-driven leading enterprises + regional segmented markets'.

The 'Blue Book' sorts out the definition of medical aesthetics, the definition and classification of medical aesthetics injection products, the industrial chain of medical aesthetics injection products, relevant regulations and supervision systems for medical aesthetics injection products in China, as well as the driving factors for the development of the medical aesthetics injection product industry in China. For more detailed content, please refer to the full report.

Hyaluronic acid (English name: Hyaluronic acid, abbreviated as HA), also known as hyaluronan, is an indispensable high molecular polysaccharide in living organisms. Its molecular structure is mainly composed of alternating N-acetylglucosamine and D-glucuronate monomers.

Hyaluronic acid has a broad application prospect in various fields due to its unique functions such as water retention and lubrication. Among them, hyaluronic acid used as an injectable product for medical aesthetics is of medical grade and has been classified as Class III medical devices, under strict supervision.

 Source: Analysis by Frost & Sullivan

As one of the medical beauty injection products with the longest application history and the widest range of uses globally, the safety and efficacy of hyaluronic acid have long been fully verified by the market and consumers.

According to data from the International Society of Aesthetic Plastic Surgery (ISAPS), the global number of hyaluronic acid (HA) injections exceeded 6.3 million in 2024, accounting for 30.9% of all non-surgical medical aesthetic procedures, a 5.2% increase compared to 2023. This data indicates that HA injections still have significant growth potential. As Chinese consumers' understanding of medical aesthetics deepens, high-end HA products such as GHD's ReLuma & Dermalift, Allergan's Juvederm & Radiesse, and Haohai Shengke's Haima & Moon White are expected to increasingly be favored by the market.

Source: Public information, analysis by Frost & Sullivan

The 'Blue Book' sorts out the definition, classification, advantages, development history, application analysis, industry development analysis of hyaluronic acid, the analysis of the Chinese hyaluronic acid raw material market, the current industry situation, the production path and process route of hyaluronic acid, listed products, hyaluronic acid for injection and filling, hyaluronic acid for dermal fillers, and the future development trend. For more detailed content, please refer to the full report.

Collagen, also known as collagen peptide, is a vitally important biopolymer that accounts for about 30% of the total protein content in the human body and is one of the most abundant protein types. Collagen constructs a strong scaffold system within the human body, supporting not only the basic structure of connective tissues such as skin, muscles, bones, tendons, and ligaments but also deeply participating in the realization of various biological functions such as skin renewal, organ protection, and blood coagulation. It plays a central role in maintaining overall health and physiological functions.

Approximately 29 different types of collagen have been identified so far. Collagens can be classified into type I, type II, and type III collagen according to their discovery order, and so on; based on their function, collagen can be divided into fibrous collagen and non-fibrous collagen; depending on their source, collagen can be divided into recombinant collagen and animal-derived collagen.

Source: Analysis by Frost & Sullivan

Shuangmei Biotechnology's porcine-derived collagen products are the earliest to be launched for medical beauty collagen injections in China. Developed based on the extraction process of American bovine collagen, they were first marketed in Taiwan, China in 2008, and subsequently obtained the NMPA approval in 2009, officially launching on the Chinese mainland. Fiman Biotechnology has been deeply involved in the field of biomedical materials for many years, relying on biomolecular research and technological innovation to build technical barriers. Its core product, FILLDERM collagen filler, became China's first bovine collagen filler to obtain a Class III medical device certificate.

In 2021, the medical beauty injectable recombinant collagen product ViviMe from Jinbo Biotechnology was successfully approved, becoming China's first such product, setting off a craze for recombinant collagen injections. More companies in the recombinant collagen industry are also accelerating the registration and application for medical beauty injectable collagen products.

Source: Analysis by Frost & Sullivan

Recombinant collagen is prepared using synthetic biology technology and features no viral risk, low immunogenicity, and high purity. It is suitable for sensitive skin and medical aesthetic injection applications. Animal-derived collagen comes from natural extraction and has excellent biocompatibility. Its mechanical properties and tissue repair effects have been verified through long-term use.

Currently, several companies are actively deploying in the collagen field, continuously advancing technological upgrades and capacity building. With the expansion of market demand, more related products are expected to be launched in the future, bringing consumers a richer and more diverse range of choices.

Source: Analysis by Frost & Sullivan

The 'Blue Book' sorts out the definition, structure, classification, development history, mechanism of action, application scope of collagen, market analysis of collagen products, market analysis of collagen biomaterials, analysis of the collagen industry chain, production process flow of collagen, analysis of listed collagen products, and analysis of the development trend of the collagen industry. For more detailed content, please refer to the full report.

Medical aesthetics regeneration injection products typically consist mainly of biomedical polymer materials. They are usually injected into the dermis and/or subcutaneous tissue in the form of microspheres, stimulating the body's own collagen regeneration to achieve the effects of reshaping tightness, beautification, and anti-aging. Common medical aesthetics injection regeneration materials are synthetic polymers such as polylactic acid (PLA), poly has lactone (PCL), polyvinyl alcohol (PVA), and polymethyl methacrylate (PMMA).

Source: Analysis by Frost & Sullivan

As of July 2025, a total of 9 domestic companies have had multiple polylactic acid medical aesthetics injection products approved, with market growth and competition becoming increasingly fierce. Avilan, produced by Changchun Shengboma, is one of the earliest products launched in China and enjoys a high market recognition. A related sharing event in April 2024 showed that Avilan's cumulative sales have reached 213,300 units. In addition, similar products from companies such as Huadong Medicine and Shangli Biotechnology are expected to be launched between 2025-2026. In the future, the competition for polylactic acid medical aesthetics injection products in China will become even more intense.

Source: Analysis by Frost & Sullivan

The 'Blue Book' sorts out the mechanism of action and advantage analysis of medical aesthetics regenerative injection products; the definition and principle of action of polylactic acid, its synthesis and metabolic pathways, development history, market size, analysis of listed products; the definition and application scope of polycaprolactone, its development history, listed products; as well as the future development trends of medical aesthetics regenerative injection products. For more detailed content, please refer to the full report.

Clostridium botulinum secretes a potent neurotoxin called botulinum toxin in anaerobic environments, which can cause specific neurological poisoning symptoms. Based on antigenic differences, botulinum toxin can be divided into seven types: A, B, C (C1, C2), D, E, F, and G. Currently, type A botulinum toxin is widely used in the field of medical aesthetics. It is the most neurotoxic protein that is well understood by humans and can exert significant therapeutic effects within safe limits.

Source: Literature search, Frost & Sullivan analysis

According to data analysis by Frost & Sullivan, in 2021, the market scale of botulinum toxin products in China reached RMB 4.6 billion, achieving a compound annual growth rate of 25.6% between 2017 and 2021. Benefiting from the continuous development of the injectable medical aesthetics service market and the recent approval of more types of botulinum toxin products, the overall market scale of botulinum toxin products in China is expected to further expand, reaching RMB 39 billion by 2030.

Currently, China has launched six botulinum toxin products for injection on the market, which are listed in chronological order as follows: Hengli from Lanzhou Institute of Biological Products, BOTOX from Allergan (formerly known as Eucerin), Dysport from GMP Biologics, Letybo from South Korea's Hugel (acquired by Sino Biologics), XEOMIN from Germany's Merz (acquired by Fosun Pharma), and DAXXIFY from the US' Revance (acquired by Fosun Pharma).

In addition, as of July 2024, several other botulinum toxin injections are in the stage of marketing application. Once these investigational products are approved for market entry, the market share of botulinum toxin products will further increase. The market size of botulinum toxin in China is huge and growing rapidly.

The 'Blue Book' sorts out the definition, classification, and advantages of botulinum toxin, its applications in the medical aesthetics field, measurement indicators, development history, market analysis, process routes, analysis of marketed products, analysis of ongoing research pipelines, as well as future development trends. For more detailed content, please refer to the full report.

With the booming development of the medical aesthetics industry, the emergence of new injection materials has injected new vitality into the market. By obtaining relevant qualification certifications, they continuously promote the standardized development of the medical aesthetics industry.

Hydroxyapatite (HAP), in addition to possessing excellent stability, bioactivity, and biocompatibility, does not cause irritation or rejection reactions after implantation into living organisms. It also has good bone conductivity, biodegradability, and the ability to induce bone formation. Given that human bone is mainly composed of 60% to 70% needle-like hydroxyapatite and collagen fibers, HAP is considered a material with excellent performance and near-ideal properties in the field of bone injury repair and replacement.

Artificially synthesized HAP products have high purity and consistency, and their size and shape can be controlled. They can be designed into specific forms such as microspheres. The porous structure of HAP microspheres provides an environment for fibroblasts to adhere and proliferate, allowing more collagen precursor cells to bind with them, thereby stimulating the synthesis of collagen, improving skin texture, and enhancing skin elasticity and luster. In addition, HAP can also stimulate the expression of epidermal growth factor receptors and Smad2 genes, promoting cell proliferation and tissue regeneration in skin tissue.

From 2020 to 2024, non-surgical medical aesthetics projects related to hydroxyapatite showed a good development trend. According to data from the International Society of Aesthetic Plastic Surgery (ISAPS), the number of non-surgical HPA projects globally increased from 222,785 cases in 2020 to 418,173 cases in 2024, a growth rate of 87.7%. Among them, the number of projects in 2023 was 367,646 cases, an increase of 13.7% compared to 2023, with a stable growth trend. At the same time, its percentage of the total non-surgical projects increased from 1.5% in 2020 to 2.0% in 2024, gradually expanding its market share and becoming increasingly important in the field of non-surgical medical aesthetics.

Source: Public information, analysis by Frost & Sullivan

Agarose is a natural polysaccharide derived from algae, with its main component being polygalactose. It is composed of alternating 1,3-linked β-D-galactose and 1,4-linked 3,6-endoerythritol-L-galactose units, and possesses hydrophilicity, electrical neutrality, chemical stability, malleability, as well as certain mechanical and degradation properties.

Agarose molecules exhibit a gel state within the range of 30 to 40°C. Due to their hydrophilicity, they undergo low-affinity binding with most biological molecules such as proteins during separation processes. Agarose also has good chemical stability over a wide pH range. These characteristics provide an important foundation for the preparation and application of agarose gel media.

Using agarose microspheres to prepare gels not only combines the porous nature of microspheres with the viscoelasticity of gels, but also achieves a better facial filling effect.

Source: Analysis by Frost & Sullivan

The 'Blue Book' sorts out the principles, development history, market launch, and ongoing research products of medical beauty injection products such as exosomes, hydroxyapatite, agarose, chitosan, and silk protein. It analyzes the technologies and products of relevant Chinese enterprises. For more detailed content, please refer to the full report.

Fiman (Changchun) Pharmaceutical Biotechnology Co., Ltd. (hereinafter referred to as 'Fiman Biology') was established in 2003 and is a biopharmaceutical company dedicated to the research, development, production, and sales of active collagen. The company is based on evidence-based medicine and has been deeply involved in the field of biomedical materials for over 20 years. Relying on biomolecular research and process innovation, it has built technical barriers and gradually formed a diversified business layout covering the vertical integration industry chain of collagen from 'medical cattle breeding - active collagen extraction - medical terminal products'. Fiman Biology continues to expand in areas such as biosynthetic medical devices, functional foods, and functional skincare products, aiming to meet the multi-scenario application needs of the large health industry and provide professional, safe, and efficient products and solutions for medical institutions and consumers.

Shanghai Haohai Biotechnology Co., Ltd. (collectively referred to as 'Haohai Bio' with its subsidiaries) is a technology innovation enterprise engaged in the research, development, production, and sales of medical devices and pharmaceuticals using biomedical material technology and genetic engineering technology. The company is committed to providing innovative medical products to the market through technological innovation and transformation, integration of domestic and international resources, and large-scale production, gradually achieving import substitution for related pharmaceutical products and becoming a leading enterprise in the field of biomedical materials. The company was listed on the Main Board of the Hong Kong Stock Exchange on April 30, 2015, and on the Science and Technology Innovation Board of the Shanghai Stock Exchange on October 30, 2019, becoming the first biopharmaceutical company in China to be listed on both the 'Hong Kong Stock Market + Science and Technology Innovation Board'. After more than a decade of continuous independent innovation and industrial integration, as of 2023, Haohai Bio has completed industry restructuring of biomedical materials represented by intraocular lenses, myopia prevention and control and refractive correction, ocular surface medications, medical sodium hyaluronate/sodium hyaluronate sulfate, medical chitosan, etc., achieved industrialization of recombinant human epidermal growth factor (a Class I new drug in China), and further gained industry-leading advantages in four main business areas: ophthalmology, plastic surgery and wound care, orthopedics, and anti-adhesion and hemostasis.

Dongguan Hengyi Biotechnology Co., Ltd. (hereinafter referred to as 'Hengyi Biotech') is an enterprise dedicated to research, development, and manufacturing in the field of synthetic biology. It is a platform company for medical beauty biomaterials and synthetic biology, and is a leading enterprise in international synthetic biology efficacy raw materials. The company adheres to the spirit of original innovation, utilizing cutting-edge technologies in structural biology and synthetic biology. It is currently the only company in China that has achieved mass production of recombinant human type III collagen with a true triple helix structure and resistance to high temperatures of 90°C. Centered on synthetic biology, it has constructed three major business segments: bioactive functional materials, medical aesthetics, and pharmaceutical health.

Junhe Medicine Biopharmaceutical (Hangzhou) Co., Ltd. (Junhe Medicine) was established in 2020. It is an innovative enterprise focusing on synthetic biology technology and product development. The company is committed to promoting the application of innovative recombinant protein drugs in endocrinology, neurotherapy, skin anti-aging, and new generation biomedical materials. Its goal is to provide breakthrough biopharmaceutical products and treatment plans for patients worldwide.

Jiangsu Jiangshan Juyuan Biotechnology Co., Ltd. is a high-tech enterprise focusing on the industrial design and application of bionic recombinant functional proteins. For 20 years, it has been dedicated to the research and development of recombinant collagen technology as well as the development and production of downstream products. At present, it has achieved a full industrial chain service system based on recombinant functional proteins, including gene design, strain construction, industrial design, ton-scale capacity expansion, downstream application research and development, safety and efficacy testing of downstream products. Juyuan Biotechnology is the first company to achieve large-scale fermentation production of recombinant type III collagen using Pichia pastoris and has become one of the world's largest producers of recombinant collagen with an annual output of 20 tons of high-purity solid.

Juzi Biotechnology was established in 2000 and is a biotechnology company based on technology aesthetics. It is a pioneer and leader in China's professional skin care industry based on bioactive ingredients, focusing on three major industry directions: efficacy skincare products, medical devices, functional foods, and special medical purpose formula foods.

Juzibo Biotechnology, with its proprietary synthetic biology technology as the core, designs and develops recombinant collagen, rare ginsenosides, and other bioactive components. As of June 30, 2025, it holds 186 patents and patent applications. The company's recombinant collagen technology has received the first invention patent authorization in the industry in China and has won the National Technological Invention Award and the China Patent Gold Award in 2013 and 2016 respectively. Based on the synthetic biology technology platform, Juzibo Biotechnology has built a diverse and continuously expanding product portfolio for consumers in different application scenarios.

Meibai Biotech was established in July 2020 and is a biopharmaceutical company driven by research and development, centered on breakthrough in the in vitro expression technology of human iPS cells. It has achieved the world's first large-scale mass production of collagen, which is similar to natural human extracellular matrix (ECM). Meibai Biotech has successfully constructed its own tissue-specific biomimetic extracellular matrix (ECM) expression platform, MAYBIO MATRIX.^®We are committed to building the world's largest human-derived ECM R&D, production, and sales base.

Meibai Biotechnology has strong independent scientific research and innovation capabilities, having obtained more than 20 registered patents. The company has established a headquarters in Beijing and has set up a core strategic layout in Hunan: including a scientific research institute located in the Xiangjiang New Area of Changsha City, a finished product factory in Liuyang Economic and Technological Development Zone, and a raw material factory in Kefu Equipment Headquarters Base in Yuhua District, covering a total area of 10,000 square meters. Among them, the GMP workshop and the fully automatic sterile preparation system workshop cover an area of 5,000 square meters. This base is responsible for the research, development, and production of the company's innovative regenerative repair materials; the products cover skin repair, non-invasive injection types; dosage forms cover solutions, freeze-dried fibers, gels, dressings; categories cover ECM, recombinant human collagen, lactic acid, polyethylene glycol, etc., and provides commissioned research and development, production services. It has the capacity to produce 800,000 sterile gels annually, supporting an output value of nearly 1 billion yuan.

Proseq Biotechnology Co., Ltd. is an innovative biotech company focusing on the field of anti-aging, with 'active ingredient + microsphere delivery sustained-release technology' as its core positioning. It has developed three major product lines: high-quality recombinant proteins, PDRN, and microsphere delivery sustained-release products. The company specializes in the medical aesthetics, high-end cosmetics, and health industries, providing customers with cutting-edge anti-aging technologies and product solutions.

Prokaryotic motility organisms adopt a dual-wheel drive model of 'global R&D hub + localized production'. The founder team's in-depth research on human fibroblast aging, along with international advanced high-end membrane technology and microsphere technology platforms, form a trinity of core technical barriers, driving the transformation of medical beauty raw material production from 'extensive' to 'refined'.

The 'Blue Book' introduces some companies in the medical aesthetics injection product industry, including company profiles, business segment layouts, listed products, competitive advantages, and technology platforms. For more detailed content, please refer to the full report.